Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.
about
Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemiamiR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2Childhood acute lymphoblastic leukemia: Integrating genomics into therapyChildhood Acute Lymphoblastic Leukemia: Progress Through CollaborationFunctional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALLHematopoietic stem cell transplantation in infants.Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Hematopoietic stem cell transplantation for leukemiaDevelopmentally induced Mll1 loss reveals defects in postnatal haematopoiesisChromosomal rearrangements leading to MLL gene fusions: clinical and biological aspectsDevelopment of five dual-color, double-fusion fluorescence in situ hybridization assays for the detection of common MLL translocation partnersThe MLL recombinome of acute leukemias in 2013.H2AX: functional roles and potential applications.A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells.A case of therapy-related acute lymphoblastic leukemia with t(11;19)(q23;p13.3) and MLL/MLLT1 gene rearrangementRisk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia.Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemiaThe biological and clinical significance of MLL abnormalities in haematological malignancies.Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapyNF-kappaB activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemiaDoes hematopoietic stem cell transplantation benefit infants with acute leukemia?Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesPBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged DiseaseMicroRNA-126-mediated control of cell fate in B-cell myeloid progenitors as a potential alternative to transcriptional factors.Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report.Epigenetic regulation in adult stem cells and cancers.An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome.Analysis of outcomes and prognostic factors of acute lymphoblastic leukemia patients treated by MCP841 protocol: A regional cancer center experience.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas.The MLL recombinome of acute leukemias in 2017.ZFP521 regulates murine hematopoietic stem cell function and facilitates MLL-AF9 leukemogenesis in mouse and human cells.
P2860
Q24624389-F6ABE351-B49B-4BEB-A275-3D5915C744A5Q24643476-2C114470-CBC0-4113-B9D9-416BD9DFC9A7Q24685514-2C747438-0049-4E59-88C0-69C07E98F6C6Q28080463-BCA6550A-B400-4E63-BB9F-588AE34F5D9FQ28087637-BD7509E9-65A3-4A8F-91D4-48FBF56893FBQ28475897-B7DF7FD2-34CF-455C-8627-2E17A0DB8818Q33418697-78A2A85E-7ECA-40E8-B49F-A886D836D36CQ33433407-31D0D91A-85CD-49B4-B1B2-291C0D006BD9Q34034180-948A576D-9775-427C-A015-B310BA52AC8CQ34195379-21B467ED-9BD8-49D0-98DA-174B51D37AF1Q34601806-BFCEA3F6-81D9-4281-9076-D8FF9FE6B968Q34620470-99C604D3-A026-47C8-9228-C16C1446AAC2Q34651113-7AFE2D0B-A1F7-4775-A3D3-094F42A442A1Q34982397-C4454BA4-427B-45E7-BE1F-3577DCF773A1Q34987995-F479A68C-86B8-4014-9ABF-68A54249913AQ35034197-8B4D74AE-DBD2-42A1-8B9C-94178DA547EFQ35616078-F252F7B6-C9DD-41E5-AD05-9560D2EFDF13Q35712192-86A5A439-DD54-48AF-A3DA-5C0928FFA7B1Q35847465-DB6A6982-2038-49C4-B292-FAF1407F0B50Q35850044-70F25833-B95B-49A9-B4C5-9D542CA266D6Q35854955-D0290F9D-A17D-4A77-A1BA-ED88C1E6A66FQ35940027-12EBDC4C-0B0F-48FB-8399-A347DDCFF580Q36311738-8CC88566-2B9B-4F31-8503-18E10B9C5ADFQ36318780-BEBBE84C-726C-4D2D-98A4-6A15ADF4F809Q36420748-B024D1C1-806E-44CE-98F8-05E658DA5036Q36437006-219D4563-A9AD-4D22-8FAC-528EC99773DEQ36488188-F67775CC-B5AE-4F5F-87DB-EA72C45DF66CQ36602853-2D8BB9FC-5674-411B-99E6-7FF32B5536B9Q36735211-37600131-3F40-4451-B613-674A23D0BA94Q37104006-4740DB7C-6865-4912-94D2-22BBAFF5F5E6Q37165093-5324C309-D104-4DD6-B7DA-287E75AC096FQ37306997-79673F29-0E03-4FC9-89E4-2A2CF18C2537Q37317957-E7033C34-10DA-4ACE-9EE1-FE3C1F276CBFQ37366481-45EE7523-4EA1-4F81-9A96-D4756F084966Q37401608-C7525F38-24CC-48A7-96A0-6703C25225D4Q37436345-C6F9298E-D997-4145-A2DB-03A7CF66B367Q37633585-030CF586-E140-461F-9A5A-C812CD98B73DQ37896168-F6AA9D97-70BF-4155-BD0E-8C3AC76A935CQ38681972-A8C47A2B-7113-464B-9D1F-BB14F01C2FECQ38700338-45100CBB-DF5B-4C0F-A3B4-205D86020727
P2860
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.
@ast
Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.
@en
Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.
@nl
type
label
Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.
@ast
Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.
@en
Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.
@nl
prefLabel
Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.
@ast
Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.
@en
Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.
@nl
P2093
P2860
P356
P1433
P1476
Clinical heterogeneity in chil ...... mia with 11q23 rearrangements.
@en
P2093
Baruchel A
Chessells JM
P2860
P2888
P304
P356
10.1038/SJ.LEU.2402883
P577
2003-04-01T00:00:00Z
P5875
P6179
1010107921